Malden, MA, United States of America

Mohiuddin A Quadir

This inventor holds 1 USPTO granted patent. Top assignee: Massachusetts Institute of Technology. Active years: 2023.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mohiuddin A Quadir: Innovator in Nanoparticle Drug Delivery

Introduction

Mohiuddin A Quadir is a notable inventor based in Malden, MA (US). He has made significant contributions to the field of drug delivery systems, particularly through his innovative work on nanoparticle polymer-drug conjugates.

Latest Patents

Quadir holds a patent for a "Nano-fibular nanoparticle polymer-drug conjugate for sustained dermal delivery of retinoids." This patent discloses conjugated polymers that comprise a polymer and an all-trans retinoic acid (ATRA) prodrug covalently bound to the polymer by a hydrolysable linker or a pharmaceutically acceptable salt thereof. The methods described in this patent aim to treat certain disorders effectively. In one embodiment, the conjugated polymer consists of poly (vinyl alcohol) covalently bound to ATRA through an ester linkage. He has 1 patent to his name.

Career Highlights

Mohiuddin A Quadir is affiliated with the Massachusetts Institute of Technology, where he continues to advance research in drug delivery technologies. His work has garnered attention for its potential applications in medical treatments.

Collaborations

Quadir has collaborated with esteemed colleagues such as Steven A Castleberry and Paula T Hammond, contributing to a rich environment of innovation and research.

Conclusion

Mohiuddin A Quadir's work in nanoparticle drug delivery represents a significant advancement in the field of pharmaceuticals. His innovative approach to sustained dermal delivery of retinoids showcases the potential of polymer-drug conjugates in treating various disorders.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…